Nanomedicines—A Scientific Toy or an Emerging Market?
In recent years, significant effort has been made in the development and synthesis of polymer nanoparticles for the targeted delivery of drugs. Although many of these nanocarriers have attracted the attention of the pharmaceutical industry, only a few of them have been approved so far. The growing knowledge of their interactions with biological surfaces enables an adoption of the unique properties of the nanoparticle to the physiological environment. The following section describes the criteria that need to be considered for the development and optimization of these versatile drug delivery systems and the requirements for their translation into novel nanomedicines .
KeywordsNanocrystals Nanomedicines Industry Market Regulations Developability Drugability
- Beyer S, Xie L, Grafe S, Vogel V, Dietrich K, Wiehe A et al (2014) Bridging laboratory and large scale production: preparation and in vitro-evaluation of photosensitizer-loaded nanocarrier devices for targeted drug delivery. Pharm Res 32(5):1714–1726Google Scholar
- Beyer S, Moosmann A, Kahnt AS, Ulshöfer T, Parnham MJ, Ferreirós N et al (2015) Drug release and targeting: the versatility of polymethacrylate nanoparticles for peroral administration revealed by using an optimized in vitro-toolbox. Pharm Res 32(12):3986–3998Google Scholar
- Bioalliance Pharma (2009) Doxorubicin Transdrug®: significant increased survival rate in patients with advanced hepatocellular carcinoma treated in a phase II clinical trial ParisGoogle Scholar
- Calatayud MP, Sanz B, Raffa V, Riggio C, Ibarra MR, Goya GF (2014) The effect of surface charge of functionalized FeO nanoparticles on protein adsorption and cell uptake. Biomaterials 35(24):6389–6399Google Scholar
- Dailey LA, Hernandez-Prieto R, Casas-Ferreira AM, Jones MC, Riffo-Vasquez Y, Rodriguez-Gonzalo E et al (2014) Adenosine monophosphate is elevated in the bronchoalveolar lavage fluid of mice with acute respiratory toxicity induced by nanoparticles with high surface hydrophobicity. NanotoxicologyGoogle Scholar
- European Medicines Agency (EMA) (2007) European public assessment report on Abraxane. In: (CHMP) CfMPfHUGoogle Scholar
- European Medicines Agency (EMA) (2013) Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product (EMA/CHMP/806058/2009/Rev. 02). In: Committee for medicinal products for human use (CHMP)Google Scholar
- European Medicines Agency (EMA) (2013) Reflection paper on surface coatings: general issues for consideration regarding parenteral administration of coated nanomedicine products (EMA/325027/2013). In: Committee for medicinal products for human use (CHMP)Google Scholar
- European Medicines Agency (EMA) (2013) Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. In: Committee for medicinal products for human use (CHMP)Google Scholar
- Food and Drug Administration (FDA) (2002) Liposome drug products—chemistry, manufacture, and controls; human pharmacokinetics and bioavailability; AND labeling documentation. In: Services USDoHaHGoogle Scholar
- Gao H, Zhang S, Cao S, Yang Z, Pang Z, Jiang X (2014) Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm 11(8):2755–2763Google Scholar
- Ostwald W (1900) Über die vermeintliche Isomerie des roten und gelben Quecksilberoxyds und die Oberflächenspannung fester Körper. Zeitung für physikalische Chemie 34(4):495–503Google Scholar